MKS to sell Ophir Optics unit to TTM for $650 million

MKS agreed to sell its Ophir Optics business to TTM Technologies for $650 million in cash, an estimated multiple of more than 18 times projected FY2026 adjusted EBITDA. MKS said the sale will help realize value from the business and strengthen its balance sheet; it excludes the separately operated Ophir Instruments unit and the Ophir brand. Closing is expected in Q2 2027, subject to customary adjustments, regulatory approvals, and other conditions.

Analysis

The key asymmetry is timing: MKS has announced a monetization, not received cash. With closing not expected until Q2 2027 and approvals/consents outstanding, near-term balance-sheet or valuation benefits are conditional; the sale is unlikely to justify treating proceeds as immediately available. For MKS, the durable question is whether proceeds reduce debt, fund investment, or support shareholder returns—and whether the divested earnings stream leaves the remaining portfolio with weaker growth or less defense exposure. Verify the unit’s revenue, EBITDA contribution, and MKS’s stated use of proceeds before underwriting a per-share benefit.

For TTM, the strategic fit with its defense and RF/microwave activities may create cross-selling or program-content opportunities, but those are hypotheses, not deal value today. Paying over 18x projected FY26 adjusted EBITDA makes execution and purchase financing material: integration, customer qualification, and any delay in government approvals can defer returns, while funding terms could pressure leverage or interest expense. The price is a headline multiple, not proof of value creation; confirm the EBITDA definition, closing adjustments, and financing plan.

The contrarian angle is that the seller’s premium multiple may be more informative than an assumed defense-growth windfall for the buyer. The market may credit TTM for strategic fit before evidence of synergies, while overlooking MKS’s potential earnings-per-share trade-off after divestiture. The oil-sanctions headline has no apparent connection to this transaction and should not drive positioning.

Key Decisions for Investors

• No immediate event-driven trade: wait for MKS to disclose proceeds deployment and the divested unit’s contribution to consolidated revenue/EBITDA. A verified debt reduction or credible reinvestment return would strengthen the MKSI case; material earnings dilution without a clear capital-allocation benefit would weaken it.
• Keep TTMI on a deal-risk watchlist rather than buying the strategic-fit narrative. Reassess when TTM discloses financing, expected synergies, and integration costs; rising net leverage or a purchase price materially above the announced terms would be a negative catalyst.
• For a relative-value setup, consider long MKSI / short TTMI only if the market prices in TTM synergies ahead of evidence while MKS shares fail to reflect a credible use of proceeds. Size modestly given the long closing window; exit or reassess if approvals are delayed, financing is favorable enough to remove buyer balance-sheet concerns, or TTM provides quantified returns that support the premium.
• Monitor the Q2 2027 closing timetable, regulatory and governmental approvals, and subsequent guidance. A closing delay, adverse adjustment to cash proceeds, or deterioration in the Ophir Optics outlook before close would falsify the near-term monetization thesis.